vs

Side-by-side financial comparison of B&G Foods, Inc. (BGS) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

B&G Foods, Inc. is the larger business by last-quarter revenue ($439.3M vs $321.1M, roughly 1.4× MADRIGAL PHARMACEUTICALS, INC.). B&G Foods, Inc. runs the higher net margin — -4.4% vs -18.2%, a 13.9% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs -4.7%). B&G Foods, Inc. produced more free cash flow last quarter ($-70.7M vs $-133.8M).

B&G Foods, Inc. is an American branded foods holding company based in Parsippany, New Jersey. The company was formed in 1996 to acquire Bloch & Guggenheimer, a Manhattan-based producer of pickles, relish and condiments which had been founded in 1889.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

BGS vs MDGL — Head-to-Head

Bigger by revenue
BGS
BGS
1.4× larger
BGS
$439.3M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+215.5% gap
MDGL
210.8%
-4.7%
BGS
Higher net margin
BGS
BGS
13.9% more per $
BGS
-4.4%
-18.2%
MDGL
More free cash flow
BGS
BGS
$63.1M more FCF
BGS
$-70.7M
$-133.8M
MDGL

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
BGS
BGS
MDGL
MDGL
Revenue
$439.3M
$321.1M
Net Profit
$-19.1M
$-58.6M
Gross Margin
22.5%
Operating Margin
2.5%
-18.6%
Net Margin
-4.4%
-18.2%
Revenue YoY
-4.7%
210.8%
Net Profit YoY
-356.5%
1.4%
EPS (diluted)
$-0.24
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BGS
BGS
MDGL
MDGL
Q4 25
$321.1M
Q3 25
$439.3M
$287.3M
Q2 25
$424.4M
$212.8M
Q1 25
$425.4M
$137.3M
Q4 24
$551.6M
$103.3M
Q3 24
$461.1M
$62.2M
Q2 24
$444.6M
Q1 24
$475.2M
$0
Net Profit
BGS
BGS
MDGL
MDGL
Q4 25
$-58.6M
Q3 25
$-19.1M
$-114.2M
Q2 25
$-9.8M
$-42.3M
Q1 25
$835.0K
$-73.2M
Q4 24
$-222.4M
$-59.4M
Q3 24
$7.5M
$-107.0M
Q2 24
$3.9M
Q1 24
$-40.2M
$-147.5M
Gross Margin
BGS
BGS
MDGL
MDGL
Q4 25
Q3 25
22.5%
Q2 25
20.5%
Q1 25
21.2%
96.7%
Q4 24
21.5%
Q3 24
22.2%
Q2 24
20.7%
Q1 24
22.9%
Operating Margin
BGS
BGS
MDGL
MDGL
Q4 25
-18.6%
Q3 25
2.5%
-39.7%
Q2 25
5.2%
-22.2%
Q1 25
8.4%
-57.8%
Q4 24
-46.6%
-64.8%
Q3 24
11.1%
-187.1%
Q2 24
9.9%
Q1 24
-3.3%
Net Margin
BGS
BGS
MDGL
MDGL
Q4 25
-18.2%
Q3 25
-4.4%
-39.8%
Q2 25
-2.3%
-19.9%
Q1 25
0.2%
-53.4%
Q4 24
-40.3%
-57.5%
Q3 24
1.6%
-172.0%
Q2 24
0.9%
Q1 24
-8.5%
EPS (diluted)
BGS
BGS
MDGL
MDGL
Q4 25
$-2.55
Q3 25
$-0.24
$-5.08
Q2 25
$-0.12
$-1.90
Q1 25
$0.01
$-3.32
Q4 24
$-2.81
$-2.50
Q3 24
$0.09
$-4.92
Q2 24
$0.05
Q1 24
$-0.51
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BGS
BGS
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$60.9M
$198.7M
Total DebtLower is stronger
$2.0B
$339.9M
Stockholders' EquityBook value
$470.7M
$602.7M
Total Assets
$2.9B
$1.3B
Debt / EquityLower = less leverage
4.30×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BGS
BGS
MDGL
MDGL
Q4 25
$198.7M
Q3 25
$60.9M
$295.7M
Q2 25
$54.1M
$186.2M
Q1 25
$61.2M
$183.6M
Q4 24
$50.6M
$100.0M
Q3 24
$54.7M
$232.7M
Q2 24
$40.3M
Q1 24
$42.5M
$622.5M
Total Debt
BGS
BGS
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$2.0B
$339.8M
Q2 25
$2.0B
$118.4M
Q1 25
$2.0B
$118.0M
Q4 24
$2.0B
$117.6M
Q3 24
$2.1B
$117.1M
Q2 24
$2.0B
Q1 24
$2.0B
$116.1M
Stockholders' Equity
BGS
BGS
MDGL
MDGL
Q4 25
$602.7M
Q3 25
$470.7M
$625.7M
Q2 25
$501.4M
$696.0M
Q1 25
$513.1M
$710.6M
Q4 24
$524.8M
$754.4M
Q3 24
$755.3M
$777.2M
Q2 24
$765.0M
Q1 24
$781.2M
$850.8M
Total Assets
BGS
BGS
MDGL
MDGL
Q4 25
$1.3B
Q3 25
$2.9B
$1.4B
Q2 25
$2.9B
$1.0B
Q1 25
$3.0B
$996.6M
Q4 24
$3.0B
$1.0B
Q3 24
$3.4B
$1.1B
Q2 24
$3.4B
Q1 24
$3.4B
$1.1B
Debt / Equity
BGS
BGS
MDGL
MDGL
Q4 25
0.56×
Q3 25
4.30×
0.54×
Q2 25
3.97×
0.17×
Q1 25
3.91×
0.17×
Q4 24
3.85×
0.16×
Q3 24
2.75×
0.15×
Q2 24
2.67×
Q1 24
2.61×
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BGS
BGS
MDGL
MDGL
Operating Cash FlowLast quarter
$-64.6M
$-133.5M
Free Cash FlowOCF − Capex
$-70.7M
$-133.8M
FCF MarginFCF / Revenue
-16.1%
-41.7%
Capex IntensityCapex / Revenue
1.4%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$54.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BGS
BGS
MDGL
MDGL
Q4 25
$-133.5M
Q3 25
$-64.6M
$79.8M
Q2 25
$17.8M
$-47.1M
Q1 25
$52.7M
$-88.9M
Q4 24
$80.3M
$-104.5M
Q3 24
$4.2M
$-67.0M
Q2 24
$11.3M
Q1 24
$35.1M
$-149.2M
Free Cash Flow
BGS
BGS
MDGL
MDGL
Q4 25
$-133.8M
Q3 25
$-70.7M
$79.0M
Q2 25
$11.5M
Q1 25
$42.4M
Q4 24
$71.7M
$-104.7M
Q3 24
$-679.0K
$-67.8M
Q2 24
$5.2M
Q1 24
$27.5M
$-149.5M
FCF Margin
BGS
BGS
MDGL
MDGL
Q4 25
-41.7%
Q3 25
-16.1%
27.5%
Q2 25
2.7%
Q1 25
10.0%
Q4 24
13.0%
-101.3%
Q3 24
-0.1%
-109.0%
Q2 24
1.2%
Q1 24
5.8%
Capex Intensity
BGS
BGS
MDGL
MDGL
Q4 25
0.1%
Q3 25
1.4%
0.3%
Q2 25
1.5%
0.0%
Q1 25
2.4%
0.0%
Q4 24
1.6%
0.2%
Q3 24
1.0%
1.3%
Q2 24
1.4%
Q1 24
1.6%
Cash Conversion
BGS
BGS
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
63.17×
Q4 24
Q3 24
0.56×
Q2 24
2.87×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BGS
BGS

Specialty Segment$150.5M34%
Meals Segment$110.0M25%
Spices And Flavor Solutions Segment$101.4M23%
Frozen And Vegetables Segment$77.4M18%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons